Dr. Reddy’s Launches Obesity Drug Semaglutide Under Obeda® Brand

Dr. Reddy’s Laboratories has announced the launch of its injectable semaglutide drug for obesity treatment under the brand name Obeda®. This move is seen as part of the company's strategy to expand its portfolio in metabolic diseases. Semaglutide belongs to the GLP-1 receptor agonist class and is an active ingredient proven effective in managing type 2 diabetes and weight. With the launch of this product, Dr. Reddy’s aims to enhance its competitive position in the global obesity drug market. The company stated that the production and distribution processes for Obeda® have been completed, and the drug will soon be available in pharmacies. No official statement has been made regarding financial details or sales targets. This development reflects the fruits of Dr. Reddy’s R&D investments and is expected to have a positive impact on the company's stock performance. However, market conditions and competitive dynamics should be closely monitored. This is not investment advice.